Systemic administration of a synthetic lipid a derivative, DT-5461a, reduces tumor blood flow through endogenous TNF production in hepatic cancer model of VX2 carcinoma in rabbits

Anticancer Research

Volumn 16, Issue 1, 1996, Pages 359-364

  Jimbo, Takeshi ^a   Akimoto, Toshihiko ^a   Tohgo, Akiko ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Antitumor effect; Blood flow reduction; DT 5461a; TNF ; VX2 carcinoma

Indexed keywords

DT 4361A; LIPID A DERIVATIVE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; HEPATIC ARTERY; INTRAVENOUS DRUG ADMINISTRATION; LASER DOPPLER FLOWMETRY; LIVER CANCER; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; TUMOR BLOOD FLOW;

ANIMALS; ANTINEOPLASTIC AGENTS; DISACCHARIDES; DISEASE MODELS, ANIMAL; HEPATIC ARTERY; HUMANS; INJECTIONS, INTRA-ARTERIAL; INJECTIONS, INTRAVENOUS; LIPID A; LIVER CIRCULATION; LIVER NEOPLASMS, EXPERIMENTAL; MALE; RABBITS; REGIONAL BLOOD FLOW; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029922046     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Kusama T, Soga T, Ono Y, Kumazawa E, Shioya E, Nakayama K, Uoto K and Osada Y: Synthesis and biological activities of lipid A analogs: Modification of a glycosidically bound group with chemically stable polar acidic groups and lipophilic groups on the disaccharide backbone with tetractecanoyl or N-dodecanoylglycyl groups. Chem Pharm Bull 39: 3244-3253, 1991.
2. Kumazawa E, Tohgo A, Soga T, Kusama T and Osada Y: Significant antitumor effect of a synthetic lipid A analogue, DT-5461, on murine syngeneic tumor models. Cancer Immunol Immunother 35: 307-314, 1992.
3. Kumazawa E, Akimoto T, Kita Y, Jimbo T, Joto N and Tohgo A: Intratumoral production of tumor necrosis factor augmented by endogenous interferons results in potent antitumor effects of DT-5461, a synthetic lipid A analog. J Immunother 17: 141-150, 1995.
4. 14C]antipyrine. Am J Physiol 234: H59-H66, 1978.
5. Shields AF, Larson SM, Grunbaum Z and Graham MM: Short-term thymidine uptake in normal and neoplastic tissues: Studies for pet. J Nucl Med 25: 759-764, 1984.
6. Akimoto T, Kumazawa E, Jimbo T, Joto N and Tohgo A: DT-5461a, an antitumor synthetic lipid A analog, causes selective blood flow reduction in tumor tissue. Anticancer Res 15: 105-108, 1995.
7. Kidd JG and Rous P: Transplantable rabbit carcinoma originating in a virus-induced papilloma and containing the virus in masked or altered form. J Exp Med 71: 813-838, 1940.
8. Sakane M, Tabuchi Y and Saitoh Y: Suppressive effect of doxorubicin on liver recurrence after resection of colonic VX2 cancer lesions: Difference in efficacy according to the injection protocol. Surg Today 23: 514-520, 1993.
9. Tabuchi Y, Nakamura T and Saitoh Y: Liver metastases induced by implantation of VX2 cancer into the gastrointestine. J Surg Res 50: 216-222, 1991.
10. Zagzag D, Brem S and Robert F: Neovascularization and tumor growth in the rabbit brain Am J Pathol 131: 361-372, 1988.
11. Fukushima S, Kawaguchi T, Nishida M, Juni K, Yamashita Y, Takahashi M and Nakano M: Selective anticancer effects of 3′,5′-dioctanoyl-5-fluoro-2′-deoxyundine, a lipophilic prodrug of 5-fluoro-2′-deoxyuridine, dissolved in an oily lymphographic agent on hepatic cancer of rabbits bearing VX-2 tumor. Cancer Res 47: 1930-1934, 1987.
12. Munck J-N, Riggi M, Rougier P, Chabot GG, Ramirez LH, Zhao Z, Bognel C, Ardouin P, Herait P and Gouyette A: Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor model. Cancer Res 53: 1550-1554, 1993.
13. Hayashi Y, Fukushima S, Kishimoto S, Kawaguchi T, Numata M, Isoda Y, Hirano J and Nakano M: Anticancer effects of free polyunsaturated fatty acids in an oily lymphographic agent following intrahepatic arterial administration to a rabbit bearing VX-2 tumor. Cancer Res 52: 400-405, 1992.
14. Chuang VP and Wallace S: Hepatic artery emborization in the treatment of hepatic neoplasms. Radiology 140: 51-58, 1981.
15. Goldstein HM, Wallace S, Anderson JH, Bree RL and Gianturco C: Transcatheter occlusion of abdominal tumors. Radiology 120: 539-545, 1976.
16. Zlotecki RA, Boucher Y, Lee I, Baxter LT and Jain RK: Effect of angiotensin II induced hypertension on tumor blood flow and interstitial fluid pressure. Cancer Res 53: 2466-2468, 1993.
17. Li J, Merton DA, Thakur ML, Barr J, Wilder S, O'Hara MD, Gibbons G and Goldberg B: Influence of biological response modifiers: Measurement of tumor blood flow and temperature. J Immunother 16: 175-180, 1994.
18. Jimbo T, Akimoto T and Tohgo A: Effect of combined administration of a synthetic low-toxicity lipid A derivative, DT-5461a, and indomethacin in various experimental tumor models of colon 26 carcinoma in mice. Cancer Immunol Immunother 40: 10-16, 1995.
19. Ruff MR and Gifford GE: Purification and physico-chemical characterization of rabbit tumor necrosis factor. J Immunol 125: 1671-1677, 1980.
20. Akimoto T, Kumazawa E, Jimbo T, Joto N and Tohgo A: Antitumor effect of DT-5461a, a synthetic low-toxicity lipid A analog, involves endogenous tumor necrosis factor induction subsequent to macrophage activation. Int J Immunopharmac 16: 887-893, 1994
21. Selby P, Hobbs S, Viner C, Jackson E, Jones A, Newell D, Calvert AH, McElwain T, Fearon K, Humphreys J and Shiga T: Tumor necrosis factor in man: Clinical and biological observations. Br J Cancer 56, 803-808, 1987.
22. Blick M, Sherwin SA, Rosenblum M and Gutterman J: Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 47:2986-2989, 1987.
23. Kimura K, Taguchi T, Urushizaki I, Ohno R, Abe O, Furue H, Hattori T, Ichihashi H, Inoguchi K, Majima H, Niitani H, Ota K, Saito T, Suga S, Suzuoki Y, Wakui A and Yamada K: Phase I study of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 20: 223-229, 1987.
24. Pfreundschuh MG, Steinmetz HT, Tüschen R, Schenk V, Diehl V and Schaadt M: Phase I study of intratumoral application of recombinant human tumor necrosis factor. Eur J Cancer Clin Oncol 25: 379-388, 1989.
25. Bartsch HH, Pfizenmaier K, Schroeder M and Nagel GA: Intralesional application of recombinant human tumor necrosis factor alpha induces local tumor regression in patients with advanced malignancies. Eur J Cancer Clin Oncol 25: 287-291, 1989.